- **Avant Technologies Inc.** (OTCQB: AVAI) and Austrianova have established **Klothonova, Inc.**, a new Nevada corporation, as a **50/50 joint venture** through a Joint Venture and License Agreement.  **[1740797_20250918LN76844:0]** 
- Klothonova will focus on pioneering **cell-based therapies** utilizing encapsulated Klotho-producing cells to develop treatments for Alzheimer's disease, heart disease, cancer, kidney disease, other age-related conditions, and longevity promotion.  **[1740797_20250918LN76844:0]** 
- Austrianova will contribute its proprietary cell encapsulation technology, intellectual property, and 'know-how', while Avant Technologies will provide **capital and additional resources** to support Klothonova's operations.  **[1740797_20250918LN76844:0]**

Avant Technologies and Austrianova Form Joint Venture for Klotho-Based Therapies

- AVANT TECHNOLOGIES INC. (AVAI) and SGAustria Pte. Ltd. (Austrianova) entered into a Joint Venture & License Agreement on **September 15, 2025**, to establish a new Nevada Corporation named **Klothonova, Inc.**.  **[1740797_0001740797-25-000047_exhibit10_1.htm:0]** **[1740797_0001740797-25-000047_form8_avai.htm:1]** 
- Klothonova's primary objective is to develop, maintain, and support treatments for various medical conditions, including **Alzheimer's disease, heart disease, cancer, kidney disease, and other age-related conditions**, by utilizing encapsulated Klotho-producing cells.  **[1740797_0001740797-25-000047_exhibit10_1.htm:3]** 
- AVAI will contribute up to **$1.5 million USD** in capital for Klothonova's formation and operation over the next **eighteen months**, with the potential for an additional **$8.5 million USD** in follow-up financing as a loan.  **[1740797_0001740797-25-000047_exhibit10_1.htm:0]** **[1740797_0001740797-25-000047_form8_avai.htm:1]** **[1740797_0001740797-25-000047_exhibit10_1.htm:3]** **[1740797_0001740797-25-000047_exhibit10_1.htm:4]** 
- The ownership of Klothonova will be equally split, with **50%** held by AVAI and **50%** by Austrianova, each possessing **1,500,000 shares** of common stock.  **[1740797_0001740797-25-000047_exhibit10_1.htm:0]** **[1740797_0001740797-25-000047_form8_avai.htm:1]** **[1740797_0001740797-25-000047_exhibit10_1.htm:3]** 
- Austrianova will grant an **exclusive license** for its proprietary cell encapsulation technology to Klothonova for the development of these treatments.  **[1740797_0001740797-25-000047_exhibit10_1.htm:3]**

AVANT TECHNOLOGIES (AVAI)